bs-2880R-RBITC [Conjugated Primary Antibody]
LPAR1 Polyclonal Antibody, RBITC Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: LPAR1

Immunogen Range: 281-364/364


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 1902

Swiss Prot: Q92633

Source: KLH conjugated synthetic peptide derived from human EDG2/LPAR1

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. Seems to be coupled to the G(i)/G(o), G(12)/G(13), and G(q) families of heteromeric G proteins. Stimulates phospholipase C (PLC) activity in a manner that is dependent on RALA activation.

Conjugation: RBITC

Excitation/ Emission: 540nm/625nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)

Predicted Molecular Weight: 41


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat
Dog
Cow
Sheep
Horse
Chicken

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Chen, Linmu, et al. "Lysophosphatidic acid individually induces macrophage-derived foam cell formation by blocking the expression of SRBI." Biochemical and Biophysical Research Communications (2017).Read more>>
  • Kim B et al. Targeted lipid nanoemulsions encapsulating epigenetic drugs exhibit selective cytotoxicity on CDH1-/FOXM1+ triple negative breast cancer cells.Mol Pharm. 2019 May 6;16(5):1813-1826. Read more>>
  • Chen L et al. Lysophosphatidic acid decreased macrophage foam cell migration correlated with downregulation of fucosyltransferase 8 via HNF1α. Atherosclerosis. 2019 Sep 11;290:19-30. Read more>>
VALIDATION IMAGES